Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species

X
Trial Profile

Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amphotericin B liposomal (Primary) ; Olorofim (Primary)
  • Indications Aspergillosis
  • Focus Adverse reactions; Registrational
  • Acronyms OASIS
  • Sponsors F2G
  • Most Recent Events

    • 03 Jun 2024 Planned End Date changed from 1 Nov 2025 to 1 Nov 2026.
    • 03 Jun 2024 Planned primary completion date changed from 14 Sep 2024 to 14 Sep 2025.
    • 15 Apr 2024 Planned End Date changed from 4 Mar 2025 to 1 Nov 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top